Orally inhaled migraine therapy: Where are we now?

Kevin W Stapleton

Journal: Advanced drug delivery reviews 2019;133():131-134

PMID: 30189270

Full Text on Elsevier Science View on PubMed

Abstract

Migraine is a debilitating disease that affects 9% of men and 19% of women worldwide with high socio-economic and personal impact. Surveys indicate that migraineurs are among the most dissatisfied with available therapeutic options, predominantly given via oral or injectable routes, citing side effects as the primary complaint. Orally inhaled therapies have the potential to offer faster onset of action with fewer side effects compared to existing therapies, yet development has stalled. Despite emerging therapies such as calcitonin gene-related peptide antagonists, there are still good opportunities for repositioning migraine drugs via the inhaled route.

Address: Stapleton Pharma Consulting, LLC 605 Agate St Laguna Beach, CA 92651, USA. Electronic address: [email protected].

DOI: 10.1016/j.addr.2018.08.014